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Distribution of Propranolol in Periocular Tissues:
A Comparison of Topical and Systemic Administration
Jinsong Hao,1 Michael B. Yang,2,3 Hongzhuo Liu,1 and S. Kevin Li1
Abstract
Purpose: Oral propranolol has become a promising treatment of capillary hemangiomas (CHs) despite concerns
of side effects associated with systemic beta-blockers. The objective of this study was to investigate the distri-
bution of propranolol in periocular tissues and in plasma after topical application of propranolol as compared
with intravenous and oral administration of propranolol.
Methods: Each rabbit received propranolol as ophthalmic solution (1%) in one eye (1.5mg dose), intravenous
injection (1.5mg dose), or commercially available propranolol oral solution (5mg dose). The periocular tissues
(e.g., eyelids and extraocular muscles) and blood were collected and assayed for propranolol.
Results: After topical instillation of 1.5mg propranolol, high amounts of propranolol were rapidly delivered to
the eyelids and extraocular muscles (4 - 32 mg/g at 1 h after dosing). The drug in these tissues was slowly cleared,
and significant amounts of the drug ( > 0.4 mg/g) were still present at 24 h after the topical application. After oral
administration of a clinically relevant dose of 5mg propranolol, the drug concentrations in the periocular tissues
were relatively low ( < 0.4 mg/g) at 1 h after dosing and generally undetectable at 8 h after dosing. After an
intravenous injection of 1.5mg propranolol, the drug concentrations in the eyelids and extraocular muscles were
in the range of 0.2 - 1 mg/g at 1 h after dosing. The plasma concentration of the drug after the intravenous
injection was significantly higher than that after topical application of the same dose. The higher drug con-
centrations in the periocular tissues of the treated eyes as compared with untreated eyes suggest direct pene-
tration of the drug into the periocular tissues from the administration site after topical application.
Conclusions: Topical administration can provide increased concentrations of propranolol in the periocular tis-
sues and, thus, is superior to systemic administration for the treatment of periocular CH.
Introduction
Capillary hemangiomas (CHs) are the most commonbenign tumors in infants. The CHs can cause serious
morbidity and mortality depending on their size and loca-
tion.1–3 About 7% of CHs involves the periocular regions
such as orbit and eyelids.4,5 If untreated or ineffectively
treated, complications such as astigmatism, ptosis, eyelid
closure, strabismus, amblyopia, and ultimately vision loss
may occur in patients with periocular CHs.6,7 The treatment
options for periocular CHs include topical, intralesional, or
systemic steroids, surgical excision, and a-interferon or vin-
cristine. All these treatments have potential severe side ef-
fects and varying response rates to periocular CHs.8
Leaute-Labreze et al. first discovered that propranolol, a
non-selective adrenergic beta-blocker, can inhibit growth and
cause regression of segmental CHs in 2008.9 Many physi-
cians have since become interested in treating CHs, including
periocular CHs, with oral propranolol. Oral propranolol was
found to be effective in the treatment of CHs,4,6,10–12 despite
potential side effects of systemic propranolol in infants.13,14
Systemic and chronic use of propranolol can cause brady-
cardia, hypotension, and hypoglycemia. Although oral pro-
pranolol has been suggested to be a promising therapy for
CHs, no data on the distribution of propranolol in periocular
tissues are available, which is important for the design of
dosing regimen and development of a more effective and
safer drug delivery method in treating periocular CHs.
It is hypothesized that topical drug administration is su-
perior to systemic administration by delivering high con-
centrations of drugs directly to the target periocular tissues,
minimizing systemic exposure, and avoiding undesirable
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systemic effects. The objectives of this study were to (1) study
periocular tissue distribution of propranolol in a rabbit
model after a single topical ocular instillation and (2) com-
pare these results with those after oral and intravenous ad-
ministration. The findings in this study may help physicians
optimize the dosing regimen of current oral propranolol
treatment in periocular CHs and support the use of topical
propranolol as an alternative to oral propranolol for perio-
cular CH therapy.
Methods
Materials
Propranolol hydrochloride (purity ‡ 98%) and timolol
maleate (purity ‡ 98%) were purchased from Sigma-Aldrich
(St. Louis, MO) and Spectrum Chemical MFG (Gardena,
CA), respectively. Propranolol solutions for topical and in-
travenous administration (0.5% and 1%) were prepared in
pH 7.4 phosphate-buffered saline (PBS). Oral propranolol
solution (40mg in 5mL) was purchased from Roxane Labora-
tories (Columbus, OH). Timolol maleate solution (11.7mg/mL)
was prepared in PBS and used in high-performance liquid
chromatography (HPLC) assay. PBS (pH 7.4, consisting of
0.01M phosphate buffer, 0.0027M potassium chloride, and
0.137M sodium chloride) was prepared by dissolving PBS
tablets (Sigma-Aldrich) in distilled, deionized water. Trie-
thylamine and methanol (HPLC grade) were purchased from
Fisher Scientific (Fair Lawn, NJ). All materials were used as
received.
Animals
New Zealand white rabbits (male, 2- 2.5 kg) were pur-
chased from Myrtle Rabbitry (Thompsons Station, TN). All
experiments were conducted in adherence to the Association
for Research in Vision and Ophthalmology (ARVO) State-
ment for the Use of Animals in Ophthalmic and Vision Re-
search and under the approval of the Institutional Animal
Care and Use Committee at the University of Cincinnati.
Topical administration
Three drops of 50 mL propranolol solutions (1%) were to-
pically applied *30 s apart to the lower cul-de-sac of the
right eye of each rabbit with a calibrated pipette. The eyelids
were briefly closed to simulate blinking after each topical
instillation of propranolol. The contralateral eye was not
treated and served as an untreated control. At 1, 2, 4, 8, and
24 h postadministration, blood samples were collected, the
animals were euthanized with pentobarbital (200mg/kg),
and periocular tissues were dissected from both treated and
untreated eyes. The blood samples were centrifuged at 3,400
g for 10min to yield plasma samples. The periocular tissue
samples were immediately rinsed with PBS and patted dry
with Kimwipes. The plasma and the periocular tissue
samples were stored at - 20C until assay.
The periocular tissues analyzed in this study included
inner and outer layers of upper and lower eyelids, bulbar
conjunctiva, extraocular muscles (labeled superior, inferior,
lateral, and medial muscles), and periocular fat. The superior
muscles included the superior rectus and the superior ob-
lique. The inferior muscles included the inferior rectus and
the inferior oblique. The lateral and medial muscles were the
lateral and medial rectus that had been pooled from each eye
of the animal in the assay. The inner layers of the eyelids
mainly included the palpebral conjunctiva and tarsal plate.
The outer layers of the eyelids mainly included the skin and
orbicularis muscle.
Oral administration
Commercially available propranolol oral solution of
0.625mL (5mg propranolol) was orally administered to
rabbits by using a calibrated pipette. The dose was chosen to
be similar to the clinical dose given to infants (*2mg/kg).
Blood samples were withdrawn at 1, 4, and 8 h after dosing,
and the rabbits were sacrificed immediately after blood
sampling. The periocular tissue and blood samples were
collected as described (see ‘‘Topical administration’’ section).
Intravenous administration
Propranolol solution (0.5%) of 0.3mL (1.5mg propranolol)
was intravenously administered into the marginal ear vein of
each rabbit. Blood samples were collected at 1 h after dosing,
and the rabbits were sacrificed with pentobarbital overdose.
The periocular tissue and blood samples were collected as
described (see ‘‘Topical administration’’ section).
Sample extraction
Propranolol was extracted from the plasma by using the
method of Dali et al. with minor modifications.15 Briefly,
10 mL of timolol maleate solution (11.7 mg/mL) and 100mL of
0.25M sodium hydroxide were added into 500 mL plasma
sample placed in a screw-capped glass tube and vortexed for
10 s. Timolol maleate was the internal standard in the HPLC
assay. Three milliliters of ethyl acetate were then added into
the tube, and the mixture was vortexed for 30 s. The organic
phase in the tube was separated by centrifugation at 3,400 g
for 10min, removed from the tube, and dried under a stream
of air at 50C. After drying, the residue was reconstituted in
100 mL of the mobile phase used in the HPLC assay (see
‘‘Propranolol assay’’ section). The reconstituted sample was
vortexed for 10 s and centrifuged at 3,400 g for 5min. An
aliquot of the supernatant (25mL) was then removed for the
HPLC assay. The recovery of the extraction method was
tested by adding a known amount of propranolol in the
plasma and found to be 69%– 6% (n = 5).
The periocular tissues were cut into small pieces, incu-
bated with 1mL of methanol overnight at room temperature,
and then sonicated for 30min. The mixtures were centri-
fuged at 2,200 g for 5min, and 500 mL of supernatant were
removed. Ten microliters of timolol maleate solution
(11.7 mg/mL) was added to the supernatant. The supernatant
was then vortexed for 10 s and dried under a stream of air at
50C. After drying, the residue was reconstituted in 100mL of
the HPLC mobile phase (see ‘‘Propranolol assay’’ section).
The reconstituted sample was vortexed for 10 s and centri-
fuged at 3,400 g for 5min. An aliquot of the supernatant
(25 mL) was removed from the centrifuged sample and ana-
lyzed by HPLC. The recovery of the extraction method for
the periocular tissues was determined by adding a known
amount of propranolol to the periocular tissues. The recovery
was found to be 77% – 6%, 75% – 7%, 97%– 10%, 74%– 8%,
and 79% – 20% (n = 3) for the inner layers of eyelids, outer
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layers of eyelids, bulbar conjunctiva, extraocular muscles,
and periocular fat, respectively.
Propranolol assay
The HPLC system (Prominence, Shimadzu, Columbia,
MD) consisted of CBM-20A system controller, LC-20AT
solvent delivery module, SIL-20A autosampler, SPD-20A
UV-Vis detector, and a C18 column (Microsorb-MV,
4.6mm · 150mm; Varian, Inc., Lake Forest, CA). The HPLC
assay was performed at room temperature (20C– 2C). The
mobile phase consisted of 500mL water, 500mL methanol,
and 1.0mL triethylamine, with its pH adjusted to pH 3.5
using acetic acid. The mobile phase was delivered at a flow
rate of 1.0mL/min. The injection volume was 25 mL, and the
detection wavelength was 295 nm. Calibration curves were
constructed by using solutions of known concentrations of
propranolol in the mobile phase. The calibration curves were
found to be linear (r2 > 0.999) from 10 to 500 ng/mL for the
plasma samples and from 0.025 to 75mg for the periocular
tissue samples.
Statistical analysis
In the topical application studies, the average propranolol
concentrations in the periocular tissues of treated and un-
treated eyes were calculated, respectively. The propranolol
concentrations of the periocular tissues from both eyes were
averaged in the systemic administration studies. All data are
presented as means and standard deviations (mean – SD)
with n values representing the number of replicates in each
set of data. Statistical differences were determined by using
Student’s t-tests and considered to be significant at a level of
P < 0.05.
Results
Ocular instillation
The concentrations of propranolol in the periocular tissues
of the treated eyes after topical instillation of 1% propranolol
ophthalmic solution at 1.5mg dose are shown in Fig. 1. The
concentrations of propranolol reached their peaks at*1- 2 h
after dosing in all periocular tissues studied. The highest
peak concentration was observed in the lower eyelid outer
layers (82 mg/g), followed by the upper eyelid outer layers
(12 mg/g), inferior muscles (11mg/g), bulbar conjunctiva
(7.1 mg/g), lower eyelid inner layers (6.8 mg/g), upper eyelid
inner layers (4.8 mg/g), lateral and medial muscles (4.1 mg/g),
superior muscles (3.9 mg/g), and periocular fat (1.8 mg/g).
After reaching the peak concentrations, the drug concentra-
tions in these tissues quickly decreased from 2 to 4 h post-
dosing and then slowly decreased through 24 h postdosing.
For example, the drug concentration in the inner layers of
lower eyelids decreased from the peak concentration at 1 h
postdosing to about 40% of the peak concentration at 2 h
postdosing and then to about 20% of the peak concentration
at 4 h postdosing. From 8 to 24 h postdosing, the decrease in
drug concentration in these tissues was marginal (< 20%). In
general, the drug concentrations in these tissues (except the
periocular fat) were higher than 0.4 mg/g, and could be as
high as 11mg/g, for example, in the lower eyelid outer layers,
at 24 h after dosing. Although relatively high amounts of
propranolol were delivered to the periocular tissues of ipsi-
lateral eyes after topical application, significantly lower or
insignificant amounts of propranolol were detected in the
periocular tissues of the untreated contralateral eyes (e.g.,
< 0.4 mg/g at 1 h postdosing); the concentrations of pro-
pranolol in these tissues of the untreated eyes were 1 - 2
orders of magnitudes less than those of the treated eyes. The
drug concentrations in plasma were also significantly lower
than the drug concentrations in the periocular tissues of the
treated eyes at all time points studied (Fig. 1a). The plasma
concentration peaked at 1 h postdosing (27 – 3 ng/mL) and
decreased to 12 – 2 ng/mL at 24 h postdosing.
Systemic delivery
Figure 2 shows the propranolol concentrations in the
periocular tissues after oral administration of propranolol at
FIG. 1. Concentrations of propranolol in the treated ipsi-
lateral periocular tissues (a) eyelids (e.g., upper eyelid inner
layers, upper eyelid outer layers, lower eyelid inner layers,
and lower eyelid outer layers) and (b) extraocular muscles
(superior muscles, inferior muscles, and lateral and medial
muscles), bulbar conjunctiva, and periocular fat, after topical
instillation of 1.5mg propranolol. Drug concentrations in
plasma after topical instillation are presented for compari-
son. Data represent the mean and standard deviation
(mean– SD, n = 3-4).
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5mg dose. Peak concentrations of propranolol were ob-
served at 1 h after dosing in all periocular tissues except
bulbar conjunctiva. The drug concentrations in these tissues
quickly decreased after reaching the peak concentrations and
were generally not detected at 8 h postdosing.
The drug concentrations in the periocular tissues at 1 h
after topical (1.5mg), intravenous (1.5mg), and oral (5mg)
administration of propranolol are compared in Fig. 3. After
intravenous and oral administration, the drug concentra-
tions in the periocular tissues (except the bulbar conjunctiva
and periocular fat) were in the range of 0.2–1.1 mg/g and
0.05–0.4 mg/g, respectively, which were *6–500-fold lower
as compared with those after topical application. The drug
was not detectable in the bulbar conjunctiva after oral
administration, and drug concentration in the bulbar con-
junctiva after intravenous injection was lower than that
after topical application. The periocular fat showed
the highest drug concentration among the periocular tis-
sues studied (2.4 – 0.5 mg/g) after intravenous injection,
which was comparable to that after topical application
(1.8 – 0.9 mg/g) and higher than that after oral propranolol
(0.34 – 0.03 mg/g). The plasma concentration of proprano-
lol at 1 h after intravenous injection of 1.5 mg of propran-
olol (45 – 11 ng/mL) was significantly higher (P < 0.05)
than the level observed after topical administration of
the same dose (27 – 3 ng/mL) or oral administration of
5mg of propranolol (31 – 8 ng/mL). However, the plasma
concentrations after topical and oral administration of
propranolol at the respective doses were not significantly
different (P > 0.05).
FIG. 2. Concentrations of proprano-
lol in the periocular tissues after oral
administration of a commercially
available propranolol oral solution
(Roxane) at a dose of 5mg proprano-
lol. The data represent the average
propranolol concentrations in both
eyes after administration (mean – SD,
n = 6). Missing bars indicate that the
drug was not detectable in the perio-
cular tissues at 4 and/or 8 h after oral
administration. Propranolol was not
detectable in the bulbar conjunctiva.
FIG. 3. Comparison of propranolol
concentrations in the periocular tissues
and plasma at 1 h after topical (1.5mg
dose), intravenous (1.5mg dose), and
oral (5mg dose) administration of
propranolol. The data represent the
average propranolol concentrations in
the treated eye after topical application
and in both eyes after systemic ad-
ministration (mean– SD, n= 3 - 8).
Missing bar indicates that the drug
was not detectable in the bulbar con-
junctiva at 1 h after oral administration.
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Discussion
Topical delivery
The CH is the most common periocular tumor in child-
hood that may involve the eyelids, the orbit, or both. They
can be small or extensive and superficial or deep.16 Super-
ficial CHs are near the surface of the skin and have a bright
red appearance. Deep CHs generally grow in the deeper
layers of the skin and are manifested as compressible masses
in the periocular regions. Tumor growth in the eyelids, orbit,
and extraocular muscles can cause severe ocular complica-
tions such as strabismus, amblyopia, and vision loss.16,17
Particularly, when the visual development is affected due to
tumor growth in these periocular regions, patients need to be
treated immediately.18 Oral propranolol is more clinically
acceptable for periocular CHs than corticosteroid treatments
due to the well-known side effects of corticosteroid treatment
and effectiveness of propranolol therapy.19 Currently, pro-
pranolol is only administered systemically despite the po-
tential side effects associated with systemic propranolol.
There is no generally accepted protocol for CH therapy using
oral propranolol, and the dosing regimen is usually based on
the clinical experience of physicians.
Topical application has been shown to be a preferred route
of administration for treating diseases affecting anterior tis-
sues of the eye as compared with systemic delivery. The
feasibility and effectiveness of delivering therapeutic levels
of drugs to periocular tissues after topical application have
not been well established. The literature of drug delivery to
periocular tissues is very limited. As shown in Fig. 1, the re-
sults in the present study show that topical application can
deliver relatively high concentrations of propranolol (on the
order of micrograms per gram tissue) to the periocular tissues
including the eyelids and extraocular muscles. The peak con-
centrations of the drug in the periocular tissues studied oc-
curred at *1- 2h after topical application, indicating that the
drug was rapidly taken up by the tissues from the adminis-
tration site. Significant levels of propranolol (>0.4mg/g) were
still detectable in the periocular tissues (except the periocular
fat) at 24h postdosing, thus suggesting slow clearance of the
drug from these tissues. Propranolol preferentially distributed
into the outer layers of lower eyelid after topical instillation. It
was also observed that the drug concentrations were higher in
the lower eyelid tissues and inferior muscles than in the upper
eyelid tissues and superior muscles. This was likely related to
the instillation of the topical propranolol solution in the lower
cul-de-sac during drug administration. Together, the results in
this study demonstrate the feasibility and effectiveness of de-
livering significant amounts of propranolol to the periocular
tissues after topical instillation.
To study the penetration mechanisms after topical appli-
cation, the propranolol concentrations in the untreated eyes
were compared with those in the treated eyes. The lower
drug concentrations detected in the untreated eyes as com-
pared with those in the treated eyes suggest that the drug
penetrated directly into the periocular tissues from the ad-
ministration site and that redistribution of the drug to the
tissues from systemic circulation was insignificant.
Systemic delivery
Clinically, propranolol is often orally administered at a
dose of 2mg/kg/d in a divided dose. The pharmacologically
optimal dosing interval for propranolol is every 6 h, but
patient compliance is improved if the medication is given
every 8–12 h.8,20,21 In the present study, a clinically relevant
oral dose of 5mg (*2mg/kg) was chosen but was admin-
istered in a single-dosing regimen to ensure measurable
propranolol concentrations in the periocular tissues. It was
found that propranolol was rapidly absorbed and distrib-
uted to the periocular tissues reaching their peak concen-
trations at 1 h after oral administration. The peak drug
concentrations (< 0.4 mg/g) in the periocular tissues after
5mg oral dose were significantly lower than those after
topical application at a lower dose of 1.5mg propranolol.
After reaching the peak concentrations, drug concentrations
in the tissues quickly decreased and were not detectable in
all periocular tissues at 8 h postadministration in oral ad-
ministration except in the outer layers of eyelids and the
periocular fat. This shows that oral administration at a clin-
ical dose delivered only small amounts of propranolol into
these periocular tissues compared with topical application at
a lower dose.
It is known that propranolol is subjected to extensive first-
pass metabolism after oral administration. In adults, only
about 25% of the dose reaches systemic circulation. In rare
cases, intravenous propranolol has been used to treat deep
and extensive periocular CHs.11 In the present study, the
same dose of propranolol as topical application (1.5mg
propranolol) was intravenously administered to rabbits for
comparison. After intravenous injection, the periocular fat
showed the highest drug concentration among the periocular
tissues studied (Fig. 3). This trend was also observed after
oral administration (Fig. 2) and is likely attributable to the
high lipophilicity of propranolol [log Koct (octanol/water
partition coefficient) = 3.5]. Another notable observation was
that drug concentration in the plasma after intravenous in-
jection was significantly higher than after topical application.
These results suggest that intravenous injection was less ef-
fective than topical application in delivering the drug to the
target periocular tissues but produced higher peak plasma
concentration, which may increase the likelihood of systemic
side effects.
Clinical implications
Although oral propranolol is considered a safe and well-
tolerated medication even in children,19 systemic side effects
of propranolol in the treatment of CHs have been reported,
and careful monitoring of patients with CHs during pro-
pranolol therapy is generally required.13 The results in Fig. 1
show that topical application of 1.5mg propranolol could
produce and sustain relatively high concentrations of pro-
pranolol in the periocular tissues in the animal model. Par-
ticularly, drug concentrations in the 0.4 - 90 mg/g range were
observed in eyelids and extraocular muscles, tissues in which
or tissues adjacent to areas where CHs often grow. Although
the molecular mechanisms of propranolol and the thera-
peutic concentrations of propranolol in the treatment of CHs
are not known, the half maximal inhibitory concentration
(IC50) for propranolol in inhibiting tubulogenesis in a cell
culture model has been reported.22 Considering the IC50 of
*1.7 mM (0.4 mg/g), therapeutic concentrations of proprano-
lol could be achieved in the target periocular tissues fol-
lowing topical delivery. The results in the present study
suggest that topical propranolol could be a promising
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alternative to oral propranolol in the treatment of periocular
CHs. Topically instilled propranolol could distribute into
the target tissues of the eye at pharmacologically active
concentrations with lower systemic exposure. Side effects
caused by systemic long-term administration of propranolol
in the treatment of periocular CHs might be avoided by
topical instillation. To our knowledge, this is the first sys-
tematic study of periocular tissue distribution of proprano-
lol. It should be noted that the effectiveness of topical
delivery needs to be further investigated in human clinical
study, as propranolol distribution in humans can be differ-
ent from that in animals and propranolol distribution to CH
tissues may be different from that to normal tissues. In ad-
dition, propranolol-associated cytotoxicity to the ocular tis-
sues has been observed in cell culture models.23 Although
the concentrations of propranolol in the periocular tissues in
the present study were below the level considered to be
toxic using the average half maximal inhibitory concentra-
tion of 0.4mM (103 mg/g) determined in cell proliferation
assay,23 local toxicity of ophthalmic propranolol needs to be
further investigated.
Conclusions
Distribution of propranolol in periocular tissues includ-
ing eyelids and extraocular muscles has been studied and
compared after topical, intravenous, and oral administra-
tion. The feasibility of topical delivery of propranolol to the
periocular tissues has been demonstrated. Topical instillation
produced higher concentrations of the drug in the periocular
tissues and lower concentration of the drug in plasma as
compared with intravenous injection of the same dose of
1.5mg propranolol. The drug concentrations in the eyelids
and extraocular muscles were generally maintained at higher
than 0.4mg/g for 24h after the topical application in the
present study. Conversely, oral administration of a clinically
relevant dose of 5mg propranolol produced peak concen-
trations in the target periocular tissues of at least an order of
magnitude lower than those after topical application of
1.5mg propranolol. Topical delivery of propranolol can pro-
vide higher drug concentrations in local periocular tissues
than oral and intravenous administration and, thus, may in-
crease therapeutic efficacy in the treatment of periocular CHs.
Topical propranolol could be a promising alternative to oral
propranolol in the treatment of periocular CHs.
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